Extended Data Fig. 8: Enrichment scores of PedCAP is associated with objective response in two independent studies of adult cancer patients treated with ICI.

(A–C) Correlation of PedCAP scores with CD8 gene signature derived from CIBERSORT (A, N = 66 samples), published interferon-γ signature (B, N = 66 samples) and cytolytic score (C, N = 66 samples). Values denote Spearman r. Colors denote sample origin as lymph node or one of the following: lung, soft tissues, bone, adrenal gland, kidney, brain, or unannotated tissue types. (D) PedCAP scores were significantly higher in patients experiencing partial response compared to patients experiencing progressive disease in the CA209-038 trial of nivolumab following progression on ipilimumab in adult patients with advanced melanoma (two-sided Student’s t-test, N = 49 samples). (E) PedCAP scores were significantly higher in patients experiencing partial response compared to those experiencing stable disease in the INSPIRE trial of pembrolizumab in adult patients with advanced solid tumors (two-sided Student’s t-test, *p < 0.05, N = 64 samples) (CR: complete response, PR; partial response, SD: stable disease, PD: progressive disease). (F) Multivariable Cox proportional hazards model adjusted for cohort indicates that higher PedCAP scores are associated with prolonged overall survival in the INSPIRE study (two-sided Wald test, N = 62 patients). Center indicates hazard ratio and lines indicate confidence intervals. In boxplots, boxes show median and interquartile range (IQR) and whiskers represent 1.5 × IQR. All indicated sample sizes represent biologically independent samples.